相关实验视频
Updated: Sep 10, 2025
06:10
An Ex Vivo Choroid Sprouting Assay of Ocular Microvascular Angiogenesis
Published on: August 6, 2020
5.8K
6-O-脱硫改性肝素的抗血管活性:抑制胆道新血管化
Alex Treiger Grupenmacher1, Bianca Oliveira Augusto2, Bruna Zancanelli Fetter2
1Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo 04023-062, Brazil.
International journal of molecular sciences
|August 28, 2025
概括
一种新型的肝素衍生物,6-O-脱硫肝素 (Hep-6Od),通过减少病态血管生长,降低出血风险,有望治疗与年龄相关的黄斑变性 (AMD).
科学领域:
- 眼科 眼科
- 生物化学
- 药理学
背景情况:
- 与年龄相关的黄斑变性 (AMD) 是全球不可逆转失明的主要原因.
- 病理性胆道新血管化 (CNV) 是AMD进展的驱动因素.
- 目前的治疗方法,如抗VEGF疗法,都有局限性.
研究的目的:
- 研究6-O脱硫肝素 (Hep-6Od) 在AMD治疗中的抗血管性潜力.
- 评估Hep-6Od的疗效和安全性,重点是降低抗凝活性.
- 探索Hep-6Od作为现有AMD疗法的替代方案.
主要方法:
- 选择性化学修饰肝素以产生Hep-6Od.
- 在体外测试:视网膜细胞中的细胞毒性,内皮细胞增殖,迁移和管形成.
- 在体内:激光诱导的 CNV 模型在老鼠.
- 生物化学测定:通过DSF的FGF-2相互作用,抗凝剂活性 (PT,aPTT).
主要成果:
- 在视网膜细胞中没有Hep-6Od的细胞毒性.
- 实验室研究显示,内皮细胞功能受到显著抑制.
- 这表明Hep-6Od与FGF-2相互作用.
- 在体内,Hep- 6Od 降低了 CNV 病变的大小,取决于剂量.
- 与未分离的肝素相比,Hep-6Od的抗凝效果较低.
结论:
- Hep- 6Od是一种强大的抗血管原剂,对AMD具有有利的安全性.
- 它为抗VEGF疗法提供了一个有前途的替代品,降低了出血风险.
- 需要进一步的临床验证,以确定Hep-6Od在视网膜血管疾病治疗中的作用.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
01:24Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
01:10Mechanism of Angiogenesis
5.8K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.8K